Disease and economic burden of surgery in desmoid tumors: a review

References

• Constantinidou A, Scurr M, Judson I, et al. Clinical presentation of desmoid tumors. In: Litchman C, editor. Desmoid tumors. Dordrecht the Netherlands:Springer; 2012. p. 5–16. DOI:10.1007/978-94-007-1685-8_2
   Google Scholar
• Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019 Mar;27(3):965–980. DOI:10.1007/s00520-018-4386-8
   PubMed Web of Science ®Google Scholar
• MedlinePlus. Desmoid tumor. National library of medicine 18 August 2020. [cited 13 Dec 2021]. Available from: https://medlineplus.gov/genetics/condition/desmoid-tumor/
   Google Scholar
• Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus initiative between sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC)/Soft tissue and bone sarcoma group (STBSG). Ann Oncol. 2017 Oct;28(10):2399–2408. DOI:10.1093/annonc/mdx323
   PubMed Web of Science ®Google Scholar
• Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268–274.
   PubMed Web of Science ®Google Scholar
• Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017 Jun;92(6):947–964.
   PubMed Web of Science ®Google Scholar
• Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020 Mar; 127: 96–107. DOI:10.1016/j.ejca.2019.11.013
   PubMed Web of Science ®Google Scholar
• Garcia-Ortega DY, Martín-Tellez KS, Cuellar-Hubbe M, et al. Desmoid-type fibromatosis. Cancers (Basel). 2020 Jul;12(7):1851.
   PubMed Web of Science ®Google Scholar
• Napolitano A, Mazzocca A, Spalato Ceruso M, et al. Recent advances in desmoid tumor therapy. Cancers (Basel). 2020 Aug;12(8):2135.
   PubMed Web of Science ®Google Scholar
• Seinen JM, Niebling MG, Bastiaannet E, et al. Four different treatment strategies in aggressive fibromatosis: a systematic review. Clin Transl Radiat Oncol. 2018 Aug;12:1–7. DOI:10.1016/j.ctro.2018.03.001
   PubMed Web of Science ®Google Scholar
• Janssen ML, van Broekhoven DL, Cates JM, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017 Mar;104(4):347–357.
   PubMed Web of Science ®Google Scholar
• Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989 Dec;210(6):765–769.
   PubMed Web of Science ®Google Scholar
• Tsagozis P, Stevenson JD, Grimer R, et al. Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients. Ann Med Surg (Lond). 2017 May;17:14–19.
   PubMedGoogle Scholar
• Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg. 1999 Jun;229(6):866–872. discussion 72-3. DOI:10.1097/00000658-199906000-00014
   PubMed Web of Science ®Google Scholar
• Fiore M, Crago A, Gladdy R, et al. The landmark series: desmoid. Ann Surg Oncol. 2021 Mar;28(3):1682–1689.
   PubMed Web of Science ®Google Scholar
• NCCN. Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for soft tissue sarcoma V.1.2023. ©. 2023.
   Google Scholar
• Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023 Mar;388(10):898–912.
   PubMedGoogle Scholar
• Gounder M, Robin RL, Chugh R, et al. Initial results of RINGSIDE, a phase 2/3 trial of AL102 for the treatment of desmoid tumors. Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting, Vancouver, BC, Canada. 16-19 Nov, 2022
   Google Scholar
• ClinicalTrials.gov NCT04851119. Tegavivint for the treatment of recurrent or refractory solid tumors, including lymphomas and desmoid tumors. 10 Mar 2023. [cited 20 Mar 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT04851119
   Google Scholar
• Nomura M, Rainusso N, Lee YC, et al. Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216–1227. DOI:10.1093/jnci/djz026
   PubMedGoogle Scholar
• Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the rare cancer network. Radiat Oncol. 2007 Mar;2(1):12.
   PubMedGoogle Scholar
• Anneberg M, Svane HML, Fryzek J, et al. The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol. 2022 Feb;77:102114. DOI:10.1016/j.canep.2022.102114
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Bureau of Labor Statistics. Consumer price index (CPI) databases.2022. [cited 8 Sep 2022]. Available from: https://www.bls.gov/cpi/data.htm
   Google Scholar
• He XD, Zhang YB, Wang L, et al. Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: analysis of 114 patients at a single institution. Eur J Surg Oncol. 2015 Aug;41(8):1013–1019.
   PubMed Web of Science ®Google Scholar
• Cates JM, Stricker TP, Sturgeon D, et al. Desmoid-type fibromatosis-associated Gardner fibromas: prevalence and impact on local recurrence. Cancer Lett. 2014 Oct;353(2):176–181.
   PubMed Web of Science ®Google Scholar
• Colombo C, Miceli R, Le Péchoux C, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015 Jan;51(2):186–192.
   PubMed Web of Science ®Google Scholar
• Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013 Aug;258(2):347–353. DOI:10.1097/SLA.0b013e31828c8a30
   PubMed Web of Science ®Google Scholar
• de Bruyns A, Li H, MacNeil A, et al. Evolving Practice Patterns Over Two Decades (1993–2013) in the Management of Desmoid-type Fibromatosis in British Columbia. Clin Oncol (R Coll Radiol). 2020 Apr;32(4):e102–10.
   PubMed Web of Science ®Google Scholar
• Huang K, Wang CM, Chen JG, et al. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. Am J Surg. 2014 Jun;207(6):847–854.
   PubMed Web of Science ®Google Scholar
• Mueller C, Croner R, Klein P, et al. Primary and recurrent sporadic desmoids: prognostic factors influencing recurrence-free survival after complete gross resection. Int J Surg. 2016 Jul;31:63–70.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hamada S, Kawai A, et al. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: a multicenter study in Japan. Cancer Sci. 2020 Aug;111(8):2935–2942.
   PubMed Web of Science ®Google Scholar
• Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012 Dec;19(13):4036–4042.
   PubMed Web of Science ®Google Scholar
• Turner B, Alghamdi M, Henning JW, et al. Surgical excision versus observation as initial management of desmoid tumors: a population based study. Eur J Surg Oncol. 2019 Apr;45(4):699–703.
   PubMed Web of Science ®Google Scholar
• Yang T, Liu H, Liao Z, et al. Postoperative adjuvant radiotherapy can delay the recurrence of desmoid tumors after R0 resection in certain subgroups. Front Surg. 2021 Sep;8:697793.
   PubMed Web of Science ®Google Scholar
• van Broekhoven DL, Verhoef C, Elias SG, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013 Aug;100(9):1214–1219.
   PubMed Web of Science ®Google Scholar
• Krieg AH, Wirth C, Lenze U, et al. Extra-abdominal desmoid tumours—further evidence for the watchful waiting policy. Swiss Med Wkly. 2019 Jul;149:w20107.
   PubMed Web of Science ®Google Scholar
• Penel N, Le Cesne A, Bonvalot S, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017 Sep;83:125–131.
   PubMed Web of Science ®Google Scholar
• Fiore M, MacNeill A, Gronchi A, et al. Desmoid-type fibromatosis: evolving treatment standards. Surg Oncol Clin N Am. 2016 Oct;25(4):803–826.
   PubMed Web of Science ®Google Scholar
• Timbergen MJM, Colombo C, Renckens M, et al. The prognostic role of β-catenin mutations in desmoid-type fibromatosis undergoing resection only: a meta-analysis of individual patient data. Ann Surg. 2021 Jun;273(6):1094–1101. DOI:10.1097/SLA.0000000000003698
   PubMed Web of Science ®Google Scholar
• Guo L, Wang X, Xu B, et al. Prognostic significance of CTNNB1 mutation in recurrence of sporadic desmoid tumors. Future Oncol. 2021 Feb;17(4):435–442.
   PubMed Web of Science ®Google Scholar
• Penel N, Bonvalot S, Bimbai AM, et al. Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. Clin Cancer Res. 2022 Mar 16;28(18):4105–4111. DOI:10.1158/1078-0432.CCR-21-4235
   PubMed Web of Science ®Google Scholar
• Bishop AJ, Zarzour MA, Ratan R, et al. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys. 2019 Apr;103(5):1167–1174.
   PubMed Web of Science ®Google Scholar
• Lev-Chelouche D, Abu-Abeid S, Nakache R, et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor–alpha and melphalan. Surgery. 1999 Nov;126(5):963–967.
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol. 2010 Oct;102(5):380–384.
   PubMed Web of Science ®Google Scholar
• Sakamaki Y, Kido T, Yasukawa M, et al. Wide resection of the upper right hemithorax combined with amputation of the right arm for a recurrent desmoid tumor. Jpn J Thorac Cardiovasc Surg. 2006 Aug;54(8):338–341.
   PubMedGoogle Scholar
• Catton CN, O’Sullivan B, Bell R, et al. Aggressive fibromatosis: optimisation of local management with a retrospective failure analysis. Radiother Oncol. 1995 Jan;34(1):17–22.
   PubMed Web of Science ®Google Scholar
• Gaposchkin CG, Bilsky MH, Ginsberg R, et al. Function-sparing surgery for desmoid tumors and other low-grade fibrosarcomas involving the brachial plexus. Neurosurgery. 1998 Jun;42(6):1297–1301. discussion 301-3. DOI:10.1097/00006123-199806000-00058
   PubMed Web of Science ®Google Scholar
• Sparber-Sauer M, Seitz G, von Kalle T, et al. Systemic therapy of aggressive fibromatosis in children and adolescents: report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer. 2018 May;65(5):e26943.
   PubMed Web of Science ®Google Scholar
• Newman ET, Lans J, Kim J, et al. PROMIS function scores are lower in patients who underwent more aggressive local treatment for desmoid tumors. Clin Orthop Relat Res. 2020 Mar;478(3):563–577.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Kawai A, Toguchida J, et al. Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan. Int J Clin Oncol. 2019 Nov;24(11):1498–1505.
   PubMed Web of Science ®Google Scholar
• Sobczuk P, Agnieszczak IM, Grycuk W, et al. What is the best front-line approach in patients with desmoid fibromatosis? – a retrospective analysis from a reference center. Eur J Surg Oncol. 2021 Oct;47(10):2602–2608.
   PubMed Web of Science ®Google Scholar
• Bateni SB, Gingrich AA, Jeon SY, et al. Clinical outcomes and costs following unplanned excisions of soft tissue sarcomas in the elderly. J Surg Res. 2019 Jul;239:125–135.
   PubMed Web of Science ®Google Scholar
• Mundinger GS, Prucz RB, Frassica FJ, et al. Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery. Hand (N Y). 2014 Jun;9(2):196–204.
   PubMedGoogle Scholar
• Lau D, Chan AK, Theologis AA, et al. Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients. J Neurosurg Spine. 2016 Sep;25(3):366–378.
   PubMed Web of Science ®Google Scholar
• Alamanda VK, Delisca GO, Mathis SL, et al. The financial burden of reexcising incompletely excised soft tissue sarcomas: a cost analysis. Ann Surg Oncol. 2013 Sep;20(9):2808–2814.
   PubMed Web of Science ®Google Scholar
• Franklin H, Rajan M, Tseng CL, et al. Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. J Rehabil Res Dev. 2014;51(8):1325–1330. DOI:10.1682/JRRD.2013.11.0249
   PubMedGoogle Scholar
• Labovitz JM, Shapiro JM, Satterfield VK, et al. Excess cost and healthcare resources associated with delayed diagnosis of charcot foot. J Foot Ankle Surg. 2018 Sep;57(5):952–956.
   PubMed Web of Science ®Google Scholar
• Berger A, Simpson A, Bhagnani T, et al. Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease. Am J Cardiol. 2019 Jun 15;123(12):1893–1899.
   PubMed Web of Science ®Google Scholar
• Desai U, Kharat A, Hess CN, et al. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. J Med Econ. 2021 Jan;24(1):402–409.
   PubMed Web of Science ®Google Scholar
• Gomez NG, Gaspar FW, Thiese MS, et al. Trends in incidence and correlation between medical costs and lost workdays for work-related amputations in the State of California from 2007 to 2018. Health Sci Rep. 2021 Sep;4(3):e319.
   PubMedGoogle Scholar
• Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil. 2021 Jan;102(1):115–131.
   PubMed Web of Science ®Google Scholar